CSL Ltd Features in Recent Fund Disclosures

The Australian biotechnology company CSL Ltd, listed on the ASX All Markets, has been referenced in several recent fund‑disclosure documents. The disclosures, released in late January 2026, detail CSL’s holdings across different active exchange‑traded funds (ETFs) and an index‑tracking ETF.

1. Airlie Australian Share Fund – Active ETF (AASF)

  • Portfolio disclosure date: 31 December 2025
  • CSL’s weight: 4.0 % of the fund’s total portfolio
  • Other significant holdings in the fund: BHP Group (11.3 %), Commonwealth Bank of Australia (7.2 %), and a range of other Australian equities.

The AASF report lists CSL alongside major Australian corporates, indicating the company’s importance within a diversified Australian equity strategy.

2. Perennial Income Generator Active ETF (EIGA)

  • Portfolio disclosure date: 31 December 2025
  • CSL’s presence: CSL appears in the disclosed list of securities, though the exact percentage weight is not specified in the document.
  • Other key holdings: Commonwealth Bank of Australia, BHP Group, National Australia Bank, Westpac, and several mining and resource companies.

The inclusion of CSL in EIGA’s portfolio further highlights its role as a core holding within Australian equity ETFs.

3. State Street® SPDR® S&P/ASX 50 ETF – Daily Fund Update

  • Update date: 29 January 2026
  • CSL’s shareholding: 439 shares of CSL Ltd are part of the ETF’s index basket, representing the company’s position within the S&P ASX 50 index.
  • Basket details: The ETF’s index basket for the day contained 30 January 2026 shares, including BHP Group, Commonwealth Bank of Australia, and other large Australian names.
  • Valuation: The ETF’s net asset value (NAV) on the update date was AUD 734 ,218 107.59, with the CSL shares contributing to the overall basket value.

Company Overview

CSL Ltd is a biotechnology company headquartered in Parkville, Australia, focused on the development, manufacture, and marketing of human plasma‑derived pharmaceutical and diagnostic products. Key product areas include vaccines, infection and pain medicines, skin disorder treatments, antivenoms, anticoagulants, and immunoglobulins.

  • Market Capitalisation: AUD 87 036 157 952
  • Price‑earnings Ratio: 19.91
  • Stock price (28 January 2026): AUD 179.4
  • 52‑week high (2 February 2025): AUD 277.92
  • 52‑week low (28 October 2025): AUD 168

The company’s inclusion in multiple actively managed ETFs and a benchmark index ETF underscores its significance in the Australian healthcare and biotechnology sector.